ATE419855T1 - Therapie für hormonersatz und depression enthaltend dienogest - Google Patents

Therapie für hormonersatz und depression enthaltend dienogest

Info

Publication number: ATE419855T1
Authority: AT; Austria
Prior art keywords: therapy; hormone replacement; depression containing; dienogest; containing dienogest
Prior art date: 2003-06-25

Application number

AT04744181T

Other languages

English (en)

Inventor

Ina Rudolph

Thomas Graser

Original Assignee

Bayer Schering Pharma Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-06-25

Filing date

2004-06-25

Publication date

2009-01-15

2004-06-25 Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag

2009-01-15 Application granted granted Critical

2009-01-15 Publication of ATE419855T1 publication Critical patent/ATE419855T1/de

Links

AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 title abstract 2
229960003309 dienogest Drugs 0.000 title abstract 2
229940088597 hormone Drugs 0.000 title 1
239000005556 hormone Substances 0.000 title 1
238000002560 therapeutic procedure Methods 0.000 title 1
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 1
238000011260 co-administration Methods 0.000 abstract 1
239000000262 estrogen Substances 0.000 abstract 1
229940011871 estrogen Drugs 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
239000000583 progesterone congener Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Reproductive Health (AREA)
Dermatology (AREA)
Psychiatry (AREA)
Orthopedic Medicine & Surgery (AREA)
Gynecology & Obstetrics (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Anesthesiology (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)
Injection Moulding Of Plastics Or The Like (AREA)
Surface Treatment Of Glass Fibres Or Filaments (AREA)
Lubricants (AREA)

AT04744181T 2003-06-25 2004-06-25 Therapie für hormonersatz und depression enthaltend dienogest ATE419855T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US48215403P	2003-06-25	2003-06-25
US48843903P	2003-07-21	2003-07-21
PCT/IB2004/002535 WO2004112797A1 (en)	2003-06-25	2004-06-25	Hormone replacement- and depression therapy comprising dienogest

Publications (1)

Publication Number	Publication Date
ATE419855T1 true ATE419855T1 (de)	2009-01-15

Family

ID=33544504

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04744181T ATE419855T1 (de)	2003-06-25	2004-06-25	Therapie für hormonersatz und depression enthaltend dienogest

Country Status (11)

Country	Link
US (2)	US20050032758A1 (de)
EP (1)	EP1635843B1 (de)
JP (1)	JP2007528358A (de)
AT (1)	ATE419855T1 (de)
DE (1)	DE602004018921D1 (de)
DK (1)	DK1635843T3 (de)
ES (1)	ES2320662T3 (de)
PL (1)	PL1635843T3 (de)
PT (1)	PT1635843E (de)
SI (1)	SI1635843T1 (de)
WO (1)	WO2004112797A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102004019743B4 (de)	2004-04-20	2008-11-27	Bayer Schering Pharma Aktiengesellschaft	Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
MXPA06013418A (es) *	2004-05-26	2007-01-23	Wyeth Corp	Composiciones y metodos para el tratamiento del trastorno disforico premenstrual.
EP1774970A1 (de) *	2005-10-13	2007-04-18	Bayer Schering Pharma AG	Verfahren zur Herstellung eines einphasigen pharmazeutischen Präparates zur Therapie der dysfunktionellen uterinen Blutung, enthaltend Ethinylestradiol und Dienogest
US8153616B2 (en)	2005-10-17	2012-04-10	Bayer Pharma Aktiengesellschaft	Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
EP1930010A1 (de)	2006-10-20	2008-06-11	Bayer Schering Pharma Aktiengesellschaft	Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido
EP4733407A3 (de) *	2008-12-23	2026-08-19	Quest Diagnostics Investments LLC	Massenspektrometrietest für östrogene verbindungen
BE1027858B1 (fr) *	2019-12-13	2021-07-14	Georges Debled	Composition pharmaceutique pour la contraception chez la femme

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US165209A (en) *		1875-07-06		Improvement in automatic shut-off attachments for water-closets
US198671A (en) *		1877-12-25		Improvement in apparatus for recovering alkali from waste solutions
DE19525017A1 (de) *	1995-06-28	1997-01-02	Schering Ag	Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
PT956024E (pt) *	1996-07-26	2004-10-29	Wyeth Corp	Metodo contraceptivo oral monofasico e estojo ("kit") compreendendo uma combinacao de uma progestina e estrogenio
US6306914B1 (en) *	1997-10-21	2001-10-23	Columbia Laboratories, Inc.	Progestin therapy for maintaining amenorrhea
CA2267743C (en) *	1999-03-30	2011-07-26	Robert F. Casper	Low dose estrogen interrupted hormone replacement therapy
DE60216630T2 (de) *	2001-11-15	2007-09-20	Pantarhei Bioscience B.V.	Verwendung von östrogen in kombination mit progestogen für die hormonsubstitutiionstherapie
WO2003082299A1 (en) *	2002-04-03	2003-10-09	Jencap Research Ltd.	Improved hormone replacement therapy

2004
- 2004-06-25 PL PL04744181T patent/PL1635843T3/pl unknown
- 2004-06-25 WO PCT/IB2004/002535 patent/WO2004112797A1/en not_active Ceased
- 2004-06-25 PT PT04744181T patent/PT1635843E/pt unknown
- 2004-06-25 DE DE602004018921T patent/DE602004018921D1/de not_active Expired - Lifetime
- 2004-06-25 US US10/875,521 patent/US20050032758A1/en not_active Abandoned
- 2004-06-25 EP EP04744181A patent/EP1635843B1/de not_active Expired - Lifetime
- 2004-06-25 ES ES04744181T patent/ES2320662T3/es not_active Expired - Lifetime
- 2004-06-25 SI SI200431086T patent/SI1635843T1/sl unknown
- 2004-06-25 AT AT04744181T patent/ATE419855T1/de active
- 2004-06-25 JP JP2006516611A patent/JP2007528358A/ja active Pending
- 2004-06-25 DK DK04744181T patent/DK1635843T3/da active
2012
- 2012-03-02 US US13/411,131 patent/US20120225853A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP2007528358A (ja)	2007-10-11
PL1635843T3 (pl)	2009-06-30
EP1635843A1 (de)	2006-03-22
US20050032758A1 (en)	2005-02-10
PT1635843E (pt)	2009-04-07
US20120225853A1 (en)	2012-09-06
WO2004112797A1 (en)	2004-12-29
SI1635843T1 (sl)	2009-06-30
EP1635843B1 (de)	2009-01-07
ES2320662T3 (es)	2009-05-27
DK1635843T3 (da)	2009-05-04
DE602004018921D1 (de)	2009-02-26

Legal Events

Date

Code

Title

Description

2009-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1635843

Country of ref document: EP

Publication	Publication Date	Title
BR0316203A (pt)	2005-10-04	Uso de um agente antialérgico e um esteróide para tratar rinite alérgica
TW200716137A (en)	2007-05-01	Tanaproget compositions containing ethinyl estradiol
PL2131847T3 (pl)	2011-05-31	Lek zawierający przynajmniej jeden gestagen
WO2002092102A3 (en)	2003-03-20	Treatment of conditions relating to hormone deficiencies by administration of progestins
BR0011172A (pt)	2002-02-19	Derivados do 4,5-diaril-3(2h)-furanona como inibidores de cliclooxigenase-2
MY137766A (en)	2009-03-31	Exemestane as chemopreventing agent
CY1107906T1 (el)	2013-09-04	Φαρμακευτικη συνθεση που περιλαμβανει παραγωγα οιστετρολης για χρηση στην θεραπεια κατα του καρκινου
PT1421099E (pt)	2005-05-31	Esteres de 17-alfa, 21-di-hidroxipregneno como agentes anti-androgenicos
WO2005077968A8 (en)	2006-11-16	17-methylene-or 17 - spiro - cyclopropane 7 - substituted estra - 1, 3, 5 (10) - triene derivatives with anti - estrogenic activity
AR040130A1 (es)	2005-03-16	Esteres de etonogestrel, su uso como anticopceptivo y para el tratamiento de desordenes ginecologicos
ATE382355T1 (de)	2008-01-15	Zusammensetzung, enthaltend ein androgenes 11-b- halogensteroid und ein gestagen sowie m nnliches kontrazeptivum auf basis dieser zusammensetzung
BR0308660A (pt)	2005-01-25	C-17 espirolactonização e 6,7 oxidação de esteróides
PL1635843T3 (pl)	2009-06-30	Hormonalna terapia zastępcza i leczenie depresji obejmujące dienogest
CY1110173T1 (el)	2015-01-14	Χρηση της (11 beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one στη θεραπεια μειζωνος καταθλιπτικης διαταραχης
EP1857111A3 (de)	2009-03-04	Verwendung einer Kombination eines Aromatasehemmers, eines Progestins und eines Oestrogens zur Behandlung von Endometriose
PE20050665A1 (es)	2005-11-02	ESTROGENOS SELECTIVOS DE 8ß-VINIL-ESTRA-1,3,5(10)-TRIEN-3,17ß-DIOL Y 17ß-FLUOR-9-VINIL-ESTRA-1,3,6(10)-TRIEN-3,16ALFA-DIOL
MX2009000950A (es)	2009-02-04	Uso del antagonista del receptor de glucocorticoide para el tratamiento de padecimientos infecciosos.
AU2003285485A1 (en)	2004-03-03	5 ANDROSTEN-3Beta-OL STEROID INTERMEDIATES AND PROCESSES FOR THEIR PREPARATION
BR9906862A (pt)	2001-11-27	Uso de uma quantidade eficaz de um agente desubstituição hormonal para o tratamento demenopausa humana e de endometriose
AR018313A1 (es)	2001-11-14	Kit anticonceptivo que comprende medios para la administracion diaria de un agente anticonceptivo, uso de un compuesto esteroide que tiene un perfil deactividad que combina inherentemente las actividades progestagenicas y estrogenicas y un metodo anticonceptivo
BR0309621A (pt)	2005-02-09	Uso de estrógenos conjugados em combinação com trimegestona na terapia de substituição de hormÈnios
CY1110463T1 (el)	2015-04-29	Θεραπεια ορμονικης αντικαταστασης και καταθλιψης που περιλαμβανει διενογεστη
UA4216U (uk)	2005-01-17	Спосіб лікування системного червоного вовчака